January 16th 2021, 3:30pm
A flow cytometric score developed in 2012, which uses 4 parameters to distinguish low-grade myelodysplastic syndromes (MDS) from nonclonal cytopenias, is simple and practical for screening patients with MDS, according to research published in the American Journal of Translational Research.
January 15th 2021, 8:07pm
New research underscores the substantial economic burden associated with early discontinuation of guideline-recommended hypomethylating agent (HMA) therapy among patients with refractory anemia with excess blasts, a diagnosis that substantially overlaps with higher-risk myelodysplastic syndrome (MDS).
January 9th 2021, 9:00pm
A recent study evaluated the content validity of patient-reported outcome instruments used in low-risk myelodysplastic syndrome (MDS).
January 7th 2021, 5:15pm
Complete response to first-line therapy, as determined by the International Working Group 2006 response criteria, can be used as a surrogate end point for overall survival in higher-risk patients with myelodysplastic syndromes (MDS), according to a study published in Cancer Medicine.
January 2nd 2021, 1:15pm
Integrating novel parameters into conventional risk stratification systems may better define patient subgroups in myelodysplastic syndromes (MDS), thus creating a more enhanced classification and prognostic scoring system for patients, say researchers.
January 1st 2021, 9:00pm
Questions remain about the optimal approach to transfusion management in myelodysplastic syndromes (MDS), particularly in the outpatient setting, leading a pair of researchers to review current evidence.
December 23rd 2020, 8:32pm
With a goal of moving toward more individualized therapeutic approaches, researchers said future advancements in understanding myelodysplastic syndrome (MDS) molecular mechanisms are needed to offer clinical decision making guidance.
December 19th 2020, 2:00pm
Their work may help to further understanding of the molecular mechanisms of hypomethylating agents (HMAs) and offer a guide for determining which patients are likely to respond to such treatment.
December 18th 2020, 3:16pm
For patients who are resistant to hypomethylating agent (HMA) treatment, there are no formal treatment recommendations, but several options, spanning from novel HMAs to chemotherapy, have been or are currently being studied in the setting.
December 12th 2020, 3:47pm
The abstract, presented at the 2020 American Society of Hematology Annual Meeting and Exposition, found favorable overall survival and leukemia-free survival for these patients.
